SC-560
| SC-560 | |
|---|---|
| [[File:|frameless|220px|alt=|Chemical structure of SC-560]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
SC-560 is a selective cyclooxygenase-1 (COX-1) inhibitor, which is a type of nonsteroidal anti-inflammatory drug (NSAID). It is primarily used in research settings to study the role of COX-1 in various physiological and pathological processes.
Mechanism of Action[edit]
SC-560 selectively inhibits the enzyme cyclooxygenase-1 (COX-1), which is responsible for the conversion of arachidonic acid to prostaglandins. Prostaglandins are lipid compounds that have diverse roles in inflammation, pain, and fever. By inhibiting COX-1, SC-560 reduces the production of prostaglandins, thereby exerting anti-inflammatory and analgesic effects.
Pharmacokinetics[edit]
The pharmacokinetic profile of SC-560 has been studied in various animal models. It is known to have a high affinity for COX-1, with minimal activity against cyclooxygenase-2 (COX-2). This selectivity is important for understanding the differential roles of COX-1 and COX-2 in inflammation and other physiological processes.
Clinical Applications[edit]
While SC-560 is not used clinically, it serves as a valuable tool in research to delineate the specific contributions of COX-1 in various diseases. Studies have utilized SC-560 to explore its effects in models of cardiovascular disease, cancer, and neurodegenerative disorders.
Research Studies[edit]
Research involving SC-560 has provided insights into the role of COX-1 in platelet aggregation, gastric mucosal protection, and renal function. For instance, studies have shown that COX-1 inhibition by SC-560 can reduce platelet aggregation, which is a critical factor in the prevention of thrombotic events.
Safety and Toxicity[edit]
As with other NSAIDs, the use of SC-560 in research must consider potential side effects, such as gastrointestinal irritation and renal impairment. However, its selective inhibition of COX-1 may offer a different safety profile compared to non-selective NSAIDs.
Also see[edit]
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
